XNK Therapeutics Reports First Patient Included in Phase II Study in Multiple Myeloma

XNK Therapeutics AB announced that the first patient has been included in a Phase II clinical study to treat patients with multiple myeloma using XNK’s leading autologous natural killer cell-based candidate drug in combination with Sanofi’s anti-CD38 antibody Sarclisa.